This is a modest positive catalyst for a pre-revenue clinical-stage biotech — the Japanese patent extends IP protection into 2039, but does not change the fundamental binary risk of Phase 2 clinical data. Monitor enrollment updates for the platinum-resistant ovarian cancer trial and the SCLC combination trial; the next material catalyst will be clinical data readouts, not further patent grants.
Price Chart
Executive Summary
Allarity Therapeutics announced the Japan Patent Office granted patent No. 7917283 covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic, providing protection in Japan into 2039. This is a positive IP development for a clinical-stage company with an $18M market cap, but it does not change the company's fundamental financial position or near-term cash runway. The patent strengthens the commercial case for stenoparib in Japan, one of the world's largest pharma markets, but the drug remains in Phase 2 testing with no approved products or revenue.
Key Facts
- Japan Patent Office granted patent No. 7917283 covering the stenoparib-specific DRP companion diagnostic.
- Patent provides protection in Japan into 2039.
- Allarity has previously secured DRP patent protection in the US (into April 2042), certain European jurisdictions, and Australia.
- Stenoparib is a Phase 2 dual PARP/tankyrase inhibitor for advanced ovarian cancer, with a separate Phase 2 trial in relapsed small cell lung cancer enrolling.
- Company market cap is approximately $18M with no approved products or revenue.
Financial Impact
No direct financial impact disclosed; patent strengthens IP position for potential future commercialization in Japan.
Risk Factors
- Stenoparib remains in Phase 2 development with no guarantee of regulatory approval or commercial success.
- Company has no approved products or revenue; continued development depends on sufficient financing.
- Patent may face third-party challenges during the six-month post-grant opposition period in Japan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-100350 |
| Document: ea030557001ex99-1.htm | 0001213900-26-100350 |
| Document: 0001213900-26-100350-index-headers.html | 0001213900-26-100350 |
| Document: 0001213900-26-100350-index.html | 0001213900-26-100350 |
| Document: 0001213900-26-100350.txt | 0001213900-26-100350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9200 (−11.54%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 $0.9200 | ▼ −4.67% | ▼ −5.39% | $0.9200 (−4.67%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9200 (−5.00%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9200 (−20.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9200 (−21.37%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9200 (−24.59%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9200 (−32.85%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9200 (−30.83%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9200 (−32.35%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9200 (−35.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers